History of DiaSys Diagnostics Systems GmbH

1991

DiaSys founded by Dr. Günther Gorka, Rolf Greiner and Dr. Manfred Probst.

1991

Worldwide first liquid stable reagents to determine of enzymes and substrates in clinical chemistry.

1993

DiaSys relocates to a proprietary building in Holzheim.

1993

Launch of first turbidimetric tests.

1994

Export activities start in 17 countries.

1997

Introduction of CRP FS for inflammation testing.

1998

TruLab line of quality control products.

1999

Extensive expansion of reagent production capacity thanks to construction of a new building. Foundation of DiaSys France, the company's first subsidiary.

2000

First joint venture in China. 1st international distributor meeting.

2000

DiaSys enters instrument business with StarDust MC15 semi-automated analyzer.

2001

First step into point-of-care testing with SensoStar glucose and lactate testing device.

2003

Takeover of the clinical chemistry product activities of Merck KGaA, Darmstadt.

2003

CRP U-hs - innovative reagent for universal and high sensitive testing.

2004

Launch of reagents for food analysis.

2005

Acquisition of shares in Rolf Greiner Biochemica GmbH.

2005

Diabetes monitoring made easy with DiaSys oneHbA1c FS.

2006

15 year anniversary

2006

Foundation of DiaSys Russia and DiaSys Japan. Establishment of DiaSys Technologies for system development.

2007

Acquisition of Poles France enhances the instrument platform for DiaSys reagents. pes diagnosesysteme in Leipzig joins DiaSys group.

2008

New building at DiaSys headquarters.

2008

Introduction of respons®920 fully automated analyzer for small and medium labs.

2009

Acquisition of shares in Kovalent Ltd. in Brazil. Inauguration of DiaSys Diagnostic Products in Shanghai.

2009

InnovaStar® - POC testing in lab quality.

2010

Cooperation with JEOL Ltd. of Tokyo. Market launch BioMajesty® JCA-BM6010/C for higher throughputs - most compact and efficient.

2010

In 2010 the second member of the respons® family was launched.

2011

Celebrating 20 years DiaSys products with international distributor meeting.

2012

Alliance with Proline setting up reagent production in Indonesia.

2013

International Distributor Meeting in Dubai.

2014

Joint venture with Leadman of Bejing, Rep. of China.
DiaSys acquires diagnostic division of Piramal, India reestablishing DiaSys India with sales, marketing, R&D, production and international business center for POCT QDx® brand.

2014

DiaSys establishes subsidiary in U.S.A. Launch of respons®910VET for highest performance in veterinary diagnostics.

2015

New QDx® point-of-care product line gives immediate results for prompt therapeutic decisions.

2016

Participation in DiaServe laboratories. 25 years Choosing Quality.

2019

DiaSys introduces a new enzymatic HbA1c assay - HbA1c net FS - for diagnosis and monitoring of diabetes.

2019

DiaSys expands the respons®system family by respons®940, a clinical chemistry random access analyzer with a throughput of 640 tests/h including ISE measurements.

2020

Introduction of an immunoturbidimetric procalcitonin assay - Procalcitonin FS - for sepsis diagnosis. 

2021

DiaSys celebrates 30 years of ‘Choosing Quality’.

2021

Introduction of a COVID-19 panel consisting of rapid tests and the immunoturbidimetric assay, SARS-CoV-2 UTAB FS, for the determination of SARS-CoV-2 total antibodies.

2021

Foundation of a strategic partnership with ROBERT RIELE GmbH & Co KG, Berlin, for the exclusive marketing of the Photometer 505.

2022

Audited in November 2021, DiaSys obtained confirmation of compliance regarding requirement of Medical Device Single Audit Approach.

2023

By the end of 2023, DiaSys Diagnostic Systems GmbH have entered into an agreement with the Dutch subsidiary of Shenzhen Mindray Bio-Medical Electronics Co., Ltd. by which Mindray has acquired 75% stake in DiaSys group. 

2024

Launch of one step HbA1c analyzer respons®A1c